Orphan Drug Pricing: More Dialogue And Collaboration Needed, Says EURORDIS

Pharmaceutical companies, payers and other stakeholders need to work more collaboratively if the problems surrounding the pricing and reimbursement of orphan medicines are to be tackled successfully in Europe, says the rare disease organization EURORDIS.